GSK plc

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

37733W204
SEDOL

N/A
CIK

0001131399

www.gsk.com
LEI: 5493000HZTVUYLO1D793
FIGI: BBG000BLB481
GSK

GSK plc
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers - General
AI
PROFILER
NAME
GSK plc
ISIN
US37733W2044
TICKER
GSK
MIC
XNYS
REUTERS
GSK.N
BLOOMBERG
GSK US
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.

Fri, 21.02.2025       GSK
US37733W2044

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:

Thu, 20.02.2025       GSK
US37733W2044

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).

Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=130540&from=4

Wed, 19.02.2025       GSK
US37733W2044

NEW YORK, Feb. 18, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline.

So what: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Tue, 18.02.2025       GSK
US37733W2044

BENSALEM, Pa., Feb. 18, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") (NYSE: GSK).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GSK PLC. (GSK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE APRIL 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

Tue, 18.02.2025       GSK
US37733W2044

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:

Sun, 16.02.2025       GSK
US37733W2044

NEW YORK, Feb. 16, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE: GSK) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/GSK.

Sat, 15.02.2025       GSK
US37733W2044

SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK) between February 5, 2020 and August 14, 2022. GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Fri, 14.02.2025       GSK
US37733W2044

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:

Thu, 13.02.2025       GSK
US37733W2044

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).

Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=128958&from=4

Thu, 13.02.2025       GSK
US37733W2044

LOS ANGELES, Feb. 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 5, 2020 and August 14, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before April 7, 2025.    

We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S